Wells Fargo’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-22
| Closed | -$65 | – | 7854 |
|
|
2023
Q3 | $65 | Hold |
22
| – | – | ﹤0.01% | 6863 |
|
|
2023
Q2 | $53 | Buy |
22
+2
| +10% | +$3 | ﹤0.01% | 7041 |
|
|
2023
Q1 | $34 | Hold |
20
| – | – | ﹤0.01% | 7218 |
|
|
2022
Q4 | $35 | Buy |
20
+2
| +11% | +$5 | ﹤0.01% | 7121 |
|
|
2022
Q3 | $0 | Buy |
18
+10
| +125% | +$84 | ﹤0.01% | 7835 |
|
|
2022
Q2 | $0 | Buy |
8
+1
| +14% | +$15 | ﹤0.01% | 7930 |
|
|
2022
Q1 | $0 | Buy |
7
+3
| +75% | +$50 | ﹤0.01% | 8249 |
|
|
2021
Q4 | $0 | Hold |
4
| – | – | ﹤0.01% | 8166 |
|
|
2021
Q3 | $0 | Hold |
4
| – | – | ﹤0.01% | 7817 |
|
|
2021
Q2 | $0 | Buy |
4
+3
| +300% | +$211 | ﹤0.01% | 7752 |
|
|
2021
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 7647 |
|
|
2020
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 7289 |
|
|
2020
Q3 | $0 | Buy |
+1
| New | +$81 | ﹤0.01% | 7176 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 7066 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 7068 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6594 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 6518 |
|
Wells Fargo's TMBR Position: Q4 2023 in Review
Wells Fargo sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q4 2023, closing a stake of 22 shares — an estimated $65 sold.
Wells Fargo first reported a position in TMBR in Q3 2020 and held it in 13 quarters. The position peaked at $65 in Q3 2023. 0 funds tracked by Wall St. Rank hold TMBR as of Q4 2023.
- Wells Fargo reported no remaining Timber Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Wells Fargo sold 22 Timber Pharmaceuticals, Inc. shares in Q4 2023, an estimated $65.
- Wells Fargo first reported a position in Timber Pharmaceuticals, Inc. in Q3 2020 and held it in 13 quarters.
- Wells Fargo's Timber Pharmaceuticals, Inc. position peaked at $65 in Q3 2023.
- 0 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q4 2023.
Based on Wells Fargo's 13F filing for Q4 2023, filed 9 Feb 2024.